# US 2004/0082004 A1 · Highly efficient method of screening antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082004 A1
- Document ID: US20040082004A1
- Status: Published application
- Kind: A1
- Application number: 10/432,409
- Filed: 2003-05-22
- Published: 2004-04-29
- Earliest claimed: 2000-11-24
- Inventors: Kiyotoshi Kaneko
- Web page: https://patentgrep.com/patent/US20040082004A1

## CPC

- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C07K 16/005: {constructed by phage libraries}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- G01N 33/6803: {General methods of protein analysis not limited to specific proteins or families of proteins}
- G01N 33/6845: {Methods of identifying protein-protein interactions in protein mixtures}
- G01N 33/6854: {Immunoglobulins}
- C07K 2317/622: Single chain antibody (scFv)
- G01N 2550/00: Electrophoretic profiling, e.g. for proteome analysis
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides a method in which antibodies against target proteins contained in samples are screened with high efficiency. Samples including protein groups are treated with two-dimensional electrophoresis, the aforementioned protein groups are developed on a two-dimensional electrophoretic gel as an individual spot protein, the spot protein that had been developed is visualized after being transcribed onto a solid phase, then, after isolating each of the spot proteins, it is reacted with a phage antibody library, antibody that bonded to the spot proteins are replicated, an operation wherein said replicated antibody is reacted with the aforementioned spot protein is conducted once or more than twice, and antibodies against specific proteins contained in the samples including protein groups are screened. As samples including protein groups, it is preferable to use a samples wherein cellular subfraction had been separated and purified beforehand and samples wherein posttranslational modification had been removed.

## Claims

### Claim 1

A highly efficient antibody screening method, wherein the method is a screening method of antibody against a specific protein contained in the sample including a protein group, comprising the following processes (a) to (c),
(a) a process wherein a sample including a protein group is treated with two-dimensional electrophoresis, and the aforementioned protein group is developed as an individual spot protein on the two-dimensional electrophoretic gel,
(b) a process wherein the spot proteins and antibody libraries are reacted, and
(c) a process wherein the antibodies bonded to the spot proteins are replicated, and the replicated antibodies are reacted with the aforementioned spot proteins once or more than twice.

### Claim 2 (depends on 1)

The highly efficient antibody screening method according to claim 1, wherein samples where its cellular subfractions had been separated and purified beforehand are used as samples including protein groups.

### Claim 3 (depends on 1, 2)

The highly efficient antibody screening method according to claim 1 or 2, wherein samples in which posttranslational modification had been eliminated are used as the samples including protein groups.

### Claim 4 (depends on 1, 2, 3)

The highly efficient antibody screening method according to any of claims 1 to 3, wherein the individual spot proteins that had been developed on the two-dimensional electrophoretic gel are reacted with the antibody libraries as spot proteins that have been transcribed onto a solid phase.

### Claim 5 (depends on 4)

The highly efficient antibody screening method according to claim 4, wherein the spot proteins that had been transcribed onto the solid phase are visualized, and after isolating each of the spot proteins, they are reacted with the antibody libraries.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The highly efficient antibody screening method according to any of claims 1 to 5, wherein a phagemid antibody library is used as the antibody library.

### Claim 7 (depends on 6)

The highly efficient antibody screening method according to claim 6, wherein the phagemid antibodies bonded to the spot proteins are infected with host cells, and phagemid antibodies are replicated.

### Claim 8 (depends on 6)

The highly efficient antibody screening method according to claim 6, wherein PCR is conducted by targeting the CDR region of the phagemid antibodies bonded to the spot proteins, followed by infecting a phagemid vector incorporating the region amplified by PCR with host cells, and replicating phagemid antibodies.
